Handbook of Contemporary Neuropharmacology, 3

Written and edited by recognized experts, this comprehensive reference is also availableA onlineA via Wiley InterScience. Provides a readily accessible reference for students, professionals and libraries alike. Editors are recognized authorities in the neuropharmacology and science field. Comprehensive reference text for active junior and senior neurobiologists. Fills an important niche as a text between research publications and clinical applications. The Handbook of Contemporary Neuropharmacology is an invaluable resource for principal investigators and working scientistsA in academia, government and industry. This three volume set it also of interest for academic physicians, postdoctoral fellows and residents, and all high-level graduate students.

DAVID R. SIBLEY, PhD, is a Senior Investigator and Chief of the Molecular Neuropharmacology Section in the National Institute of Neurological Disorders and Stroke, National Institutes of Health. His laboratory is currently investigating the molecular, cellular, and biochemical properties of dopamine receptors and their role in neuronal signaling and pathophysiological states.

ISRAEL HANIN, PhD, is Professor and Chair Emeritus in the Department of Pharmacology at Loyola University Chicago. He formerly worked at the National Institute of Mental Health, Laboratory of Preclinical Pharmacology, and at the University of Pittsburgh Department of Psychiatry. Dr. Hanin's research has focused on cholinergic mechanisms, animal models for Alzheimer's disease, and the potential role of glycosaminoglycans in the treatment of Alzheimer's disease.

MICHAEL KUHAR, PhD, is currently a Candler Professor and Georgia Research Alliance Professor of Neuropharmacology at the Yerkes Primate Center at Emory University. He previously was a professor in the Neuroscience Department at Johns Hopkins, and a branch chief at the National Institute on Drug Abuse. Dr. Kuhar has published more than 800 articles, abstracts, book chapters, reviews, and patents.

PHIL SKOLNICK, PhD, D.Sc. (hon.), is Executive Vice President and Chief Scientific Officer for DOV Pharmaceutical, Inc. He was formerly a Lilly Fellow in Neuroscience and also served as Chief of the Laboratory of Neuroscience, National Institutes of Health.

Preface	p. xi
Contributors	p. xiii

Basic Neuropharmacology	p. 1
Soup or Sparks: The History of Drugs and Synapses	p. 3
Synaptic Transmission: Intercellular Signaling	p. 39
Synaptic Transmission: Intracellular Signaling	p. 59
Neuronal Nicotinic Receptors: One Hundred Years of Progress	p. 107
Muscarinic Acetylcholine Receptors	p. 147
Norepinephrine/Epinephrine	p. 193
Dopaminergic Neurotransmission	p. 221
Serotonin Systems	p. 257
Neuropharmacology of Histamine in Brain	p. 299
Ionotropic Glutamate Receptors	p. 365
Metabotropic Glutamate Receptors	p. 421
Pharmacology of the GABA[subscript A] Receptor	p. 465
Metabotropic GABA Receptors	p. 569
Voltage-Gated Ion Chanels	p. 617
Neuropeptides	p. 669
Neurotransmitter Transporters	p. 705
Gaseous Signaling: Nitric Oxide and Carbon Monoxide as Messenger Molecules	p. 743
Mood Disorders	p. 763
Neurobiology and Treatment of Depression	p. 765
Neurotrophic Factors in Etiology and Treatment of Mood Disorders	p. 789
Antidepressant Treatment and Hippocampal Neurogenesis: Monoamine and Stress Hypotheses of Depression Converge	p. 821
Neuroendocrine Abnormalities in Women with Depression Linked to the Reproductive Cycle	p. 843
Neurobiology and Pharmacotherapy of Bipolar Disorder	p. 859
Index	p. 877
Cumulative Index	p. 915

Anxiety and Stress Disorders	p. 1
Neurobiology of Anxiety	p. 3
Pharmacotherapy of Anxiety	p. 59
Benzodiazepines	p. 93
Neuroactive Steroids in Anxiety and Stress	p. 133
Emerging Anxiolytics: Corticotropin-Releasing Factor Receptor Antagonists	p. 177
Neurobiology and Pharmacotherapy of Obsessive-Compulsive Disorder	p. 215
Schizophrenia and Psychosis	p. 249
Phenomenology and Clinical Science of Schizophrenia	p. 251
Dopamine and Glutamate Hypotheses of Schizophrenia	p. 283
Molecular Genetics of Schizophrenia	p. 321
Postmortem Brain Studies: Focus on Susceptibility Genes in Schizophrenia	p. 343
Pharmacotherapy of Schizophrenia	p. 369
Atypical Antipsychotic Drugs: Mechanism of Action	p. 411
Substance Abuse and Addictive Disorders	p. 449
Introduction to Addictive Disorders: Implications for Pharmacotherapies	p. 451
Dopaminergic and GABAergic Regulation of Alcohol-Motivated Behaviors: Novel Neuroanatomical Substrates	p. 465
Nicotine	p. 535
Psychostimulants	p. 567
MDMA and Other "Club Drugs"	p. 613
Marijuana: Pharmacology and Interaction with the Endocannabinoid System	p. 659
Opiates and Addiction	p. 691
Pain	p. 707
Neuronal Pathways for Pain Processing	p. 709
Vanilloid Receptor Pathways	p. 727
Opioid Receptors	p. 745
Advent of A New Generation of Antimigraine Medications	p. 757
Index	p. 779
Cumulative Index	p. 817

Sleep and Arousal	p. 1
Function and Pharmacology of Circadian Clocks	p. 3
Melatonin Receptors in Central Nervous System	p. 37
Narcolepsy: Neuropharmacological Aspects	p. 79
Hypocretin/Orexin System	p. 125
Prokineticins: New Pair of Regulatory Peptides	p. 163
Sedatives and Hypnotics	p. 177
Development and Developmental Disorders	p. 201
Regulation of Adult Neurogenesis	p. 203
Neurotrophic Factors	p. 221
Neurotrophins and Their Receptors	p. 237
Tourette's Syndrome and Pharmacotherapy	p. 263
Neuropharmacology of Attention-Deficit/Hyperactivity Disorder	p. 291
Psychopharmacology of Autism Spectrum Disorders	p. 319
Neurodegenerative and Seizure Disorders	p. 345
Stroke: Mechanisms of Excitotoxicity and Approaches for Therapy	p. 347
Epilepsy: Mechanisms of Drug Action and Clinical Treatment	p. 403
Pharmacotherapy for Traumatic Brain Injury	p. 443
Dementia and Pharmacotherapy: Memory Drugs	p. 461
Pharmacotherapy and Treatment of Parkinson's Disease	p. 479
Parkinson's Disease: Genetics and Pathogenesis	p. 523
Invertebrates as Powerful Genetic Models for Human Neurodegenerative Diseases	p. 567
Neuroimmunology	p. 589
Myelin Lipids and Proteins: Structure, Function, and Roles in Neurological Disorders	p. 591
Pharmacology of Inflammation	p. 621
Pharmacological Treatment of Multiple Sclerosis	p. 671
Novel Therapies for Multiple Sclerosis	p. 683
Neuropharmacology of HIV/AIDS	p. 693
Eating and Metabolic Disorders	p. 731
Leptin: A Metabolic Perspective	p. 733
Ghrelin: Structural and Functional Properties	p. 765
Mechanisms Controlling Adipose Tissue Metabolism by the Sympathetic Nervous System: Anatomical and Molecular Aspects	p. 785
Antiobesity Pharmacotherapy: Current Treatment Options and Future Perspectives	p. 815
Index	p. 845
Cumulative Index	p. 881
Table of Contents provided by Ingram. All Rights Reserved.

What is included with this book?

The New copy of this book will include any supplemental materials advertised. Please check the title of the book to determine if it should include any access cards, study guides, lab manuals, CDs, etc.

The Used, Rental and eBook copies of this book are not guaranteed to include any supplemental materials. Typically, only the book itself is included. This is true even if the title states it includes any access cards, study guides, lab manuals, CDs, etc.

FREE SHIPPING

Amazon no longer offers textbook rentals. We do!

Handbook of Contemporary Neuropharmacology, 3 Volume Set

Summary

Author Biography

Table of Contents

Supplemental Materials